Teleflex Releases New Clinical Data on UroLift and Barrigel
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: Newsfilter
- Clinical Data Release: Teleflex announced new clinical data on the UroLift™ System and Barrigel™ rectal spacer at the 2026 AUA Annual Meeting, emphasizing their importance in improving patient outcomes for benign prostatic hyperplasia (BPH) and prostate cancer, which is expected to drive market acceptance and sales growth.
- RCT Study Results: The CLEAR randomized controlled trial demonstrated that UroLift™ System patients had a catheter independence rate of 97% from days three to seven, significantly better than Rezūm's 80% (p=0.02), indicating a clear advantage in early recovery and quality of life, which may influence physician treatment choices.
- Long-term Safety Validation: Three-year data for Barrigel™ rectal spacer showed zero Grade 2+ toxicity in treated patients compared to 10% in the control group, further validating its effectiveness in protecting bowel function during radiation therapy, potentially promoting its standardization in clinical practice.
- Strategic Focus: Teleflex plans to divest its business in the second half of 2026, concentrating on critical care and high-acuity hospital markets, with new clinical data supporting its strategic transformation and enhancing its leadership position in the urology field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TFX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TFX
Wall Street analysts forecast TFX stock price to rise
7 Analyst Rating
1 Buy
5 Hold
1 Sell
Hold
Current: 131.900
Low
122.00
Averages
136.20
High
155.00
Current: 131.900
Low
122.00
Averages
136.20
High
155.00
About TFX
Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of Arrow branded intra-aortic balloon pumps and catheters, GuideLiner, Turnpike and TrapLiner catheters, Pulsar-18 T3 Self-Expanding 4F Stent and Orsiro Mission Drug Eluting Stent.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teleflex Releases New Clinical Data on UroLift and Barrigel
- Clinical Data Release: Teleflex announced new clinical data on the UroLift™ System and Barrigel™ rectal spacer at the 2026 AUA Annual Meeting, emphasizing their importance in improving patient outcomes for benign prostatic hyperplasia (BPH) and prostate cancer, which is expected to drive market acceptance and sales growth.
- RCT Study Results: The CLEAR randomized controlled trial demonstrated that UroLift™ System patients had a catheter independence rate of 97% from days three to seven, significantly better than Rezūm's 80% (p=0.02), indicating a clear advantage in early recovery and quality of life, which may influence physician treatment choices.
- Long-term Safety Validation: Three-year data for Barrigel™ rectal spacer showed zero Grade 2+ toxicity in treated patients compared to 10% in the control group, further validating its effectiveness in protecting bowel function during radiation therapy, potentially promoting its standardization in clinical practice.
- Strategic Focus: Teleflex plans to divest its business in the second half of 2026, concentrating on critical care and high-acuity hospital markets, with new clinical data supporting its strategic transformation and enhancing its leadership position in the urology field.
See More
Teleflex Declares Quarterly Dividend of $0.34
- Consistent Dividend Payment: Teleflex declares a quarterly dividend of $0.34 per share, maintaining this amount for 73 consecutive quarters, which demonstrates the company's stable cash flow and profitability, thereby boosting investor confidence.
- Dividend Yield: The forward yield of 1.05% provides investors with a reliable return, reflecting the company's robust performance in the current economic environment.
- Financial Performance Beats Expectations: In Q1 2026, Teleflex reported a non-GAAP EPS of $1.39, exceeding expectations by $0.17, with revenue of $548.3 million surpassing forecasts by $10.71 million, indicating strong market demand and operational efficiency.
- Future Growth Outlook: Teleflex anticipates pro forma revenue growth of 4.5% to 5.5% for 2026, while initiating a $1 billion stock buyback in Q2, aimed at enhancing shareholder value and preparing for upcoming divestiture closings.
See More
Baupost Group Increases Amazon Stake Amid AI Rally
- Increased Amazon Stake: Baupost Group raised its stake in Amazon by 47% in Q1, making it the hedge fund's largest disclosed U.S. equity holding by the end of March, reflecting strong confidence in the e-commerce and cloud giant.
- New Investment Positions: The fund initiated significant new positions in emerging sectors, including insurance broker Aon, payments giant Visa, and medical device maker Teleflex, showcasing its proactive strategy in diversifying investments.
- Holding Value Analysis: By the end of the quarter, Baupost's stake in Amazon was valued at approximately $650 million, surpassing long-held positions in Restaurant Brands, Wesco International, and Union Pacific, indicating expectations for Amazon's future growth.
- Philosophy Continuation: As a follower of value investing philosophy, Klarman is known for his patience and contrarian strategies, with his 1991 book 'Margin of Safety' becoming a cult classic among investors, further solidifying his influence in the investment community.
See More
Teleflex Q1 2026 Earnings Call Insights and Strategic Outlook
- Financial Performance: Teleflex reported Q1 revenues of $548.3 million and adjusted EPS of $1.39, exceeding internal expectations despite cost pressures from tariffs and acquisitions, demonstrating resilience and profitability in the market.
- Strategic Acquisitions and Divestitures: The company acquired BIOTRONIK's Vascular Intervention business in July 2025 and plans to complete the divestiture of acute care, interventional urology, and OEM businesses in the second half of 2026, which is expected to fund future capital repurchases and debt reduction.
- Share Repurchase Program: Teleflex intends to initiate up to $1 billion in stock buybacks starting in Q2 2026, aiming to enhance shareholder value while reducing $800 million in debt, reflecting the company's confidence in future growth prospects.
- Operational Efficiency Gains: The restructuring plan, expected to be completed by mid-2028, is projected to achieve approximately $50 million in annual pretax cost savings, further optimizing operational efficiency and strengthening competitive positioning in the market.
See More
Teleflex Q1 Financial Results: Revenue Up 32.3%
- Significant Revenue Growth: In Q1 2026, Teleflex reported revenue from continuing operations of $548.3 million, reflecting a 32.3% year-over-year increase, with a 5.1% rise on a pro forma adjusted constant currency basis, indicating strong performance in the medical technology sector.
- Earnings Per Share Fluctuation: The GAAP diluted EPS was $(0.11), a sharp decline from $1.14 in the prior year, while the adjusted diluted EPS stood at $1.39, slightly below last year's $1.44, reflecting challenges during the company's transformation phase.
- Stable Future Outlook: The company maintains its 2026 GAAP revenue growth guidance range of 14.40% to 15.40%, and expects adjusted diluted EPS to be between $6.25 and $6.55, demonstrating management's confidence in future performance.
- Strategic Restructuring Progress: Newly appointed CEO Jason Weidman will take office on June 8, 2026, and in conjunction with the upcoming strategic divestitures, Teleflex plans to utilize proceeds for a $1 billion share repurchase and $800 million debt repayment to enhance financial flexibility and support future growth.
See More
Teleflex Q1 Earnings Announcement Scheduled
- Earnings Release Date: Teleflex (TFX) is set to announce its Q1 earnings on May 7 before market open, with a consensus EPS estimate of $1.22, reflecting a significant year-over-year decline of 58.1%, indicating substantial profitability challenges for the company.
- Revenue Decline Forecast: The expected revenue for Q1 is $537.59 million, down 23.3% year-over-year, highlighting the overall weakness in the medical device sector and the challenges faced by Teleflex in the market.
- Historical Performance Review: Over the past two years, Teleflex has beaten EPS estimates 100% of the time and revenue estimates 63% of the time, although recent EPS estimates have seen no upward revisions, indicating analysts' cautious outlook on the company's future performance.
- Estimate Revision Trends: In the last three months, EPS estimates have experienced 7 downward revisions with no upward adjustments, while revenue estimates saw 1 upward revision and 6 downward revisions, suggesting a weakening market confidence in Teleflex's future earnings.
See More
Teleflex Releases New Clinical Data on UroLift and Barrigel
- Clinical Data Release: Teleflex announced new clinical data on the UroLift™ System and Barrigel™ rectal spacer at the 2026 AUA Annual Meeting, emphasizing their importance in improving patient outcomes for benign prostatic hyperplasia (BPH) and prostate cancer, which is expected to drive market acceptance and sales growth.
- RCT Study Results: The CLEAR randomized controlled trial demonstrated that UroLift™ System patients had a catheter independence rate of 97% from days three to seven, significantly better than Rezūm's 80% (p=0.02), indicating a clear advantage in early recovery and quality of life, which may influence physician treatment choices.
- Long-term Safety Validation: Three-year data for Barrigel™ rectal spacer showed zero Grade 2+ toxicity in treated patients compared to 10% in the control group, further validating its effectiveness in protecting bowel function during radiation therapy, potentially promoting its standardization in clinical practice.
- Strategic Focus: Teleflex plans to divest its business in the second half of 2026, concentrating on critical care and high-acuity hospital markets, with new clinical data supporting its strategic transformation and enhancing its leadership position in the urology field.
See More
Teleflex Declares Quarterly Dividend of $0.34
- Consistent Dividend Payment: Teleflex declares a quarterly dividend of $0.34 per share, maintaining this amount for 73 consecutive quarters, which demonstrates the company's stable cash flow and profitability, thereby boosting investor confidence.
- Dividend Yield: The forward yield of 1.05% provides investors with a reliable return, reflecting the company's robust performance in the current economic environment.
- Financial Performance Beats Expectations: In Q1 2026, Teleflex reported a non-GAAP EPS of $1.39, exceeding expectations by $0.17, with revenue of $548.3 million surpassing forecasts by $10.71 million, indicating strong market demand and operational efficiency.
- Future Growth Outlook: Teleflex anticipates pro forma revenue growth of 4.5% to 5.5% for 2026, while initiating a $1 billion stock buyback in Q2, aimed at enhancing shareholder value and preparing for upcoming divestiture closings.
See More
Baupost Group Increases Amazon Stake Amid AI Rally
- Increased Amazon Stake: Baupost Group raised its stake in Amazon by 47% in Q1, making it the hedge fund's largest disclosed U.S. equity holding by the end of March, reflecting strong confidence in the e-commerce and cloud giant.
- New Investment Positions: The fund initiated significant new positions in emerging sectors, including insurance broker Aon, payments giant Visa, and medical device maker Teleflex, showcasing its proactive strategy in diversifying investments.
- Holding Value Analysis: By the end of the quarter, Baupost's stake in Amazon was valued at approximately $650 million, surpassing long-held positions in Restaurant Brands, Wesco International, and Union Pacific, indicating expectations for Amazon's future growth.
- Philosophy Continuation: As a follower of value investing philosophy, Klarman is known for his patience and contrarian strategies, with his 1991 book 'Margin of Safety' becoming a cult classic among investors, further solidifying his influence in the investment community.
See More
Teleflex Q1 2026 Earnings Call Insights and Strategic Outlook
- Financial Performance: Teleflex reported Q1 revenues of $548.3 million and adjusted EPS of $1.39, exceeding internal expectations despite cost pressures from tariffs and acquisitions, demonstrating resilience and profitability in the market.
- Strategic Acquisitions and Divestitures: The company acquired BIOTRONIK's Vascular Intervention business in July 2025 and plans to complete the divestiture of acute care, interventional urology, and OEM businesses in the second half of 2026, which is expected to fund future capital repurchases and debt reduction.
- Share Repurchase Program: Teleflex intends to initiate up to $1 billion in stock buybacks starting in Q2 2026, aiming to enhance shareholder value while reducing $800 million in debt, reflecting the company's confidence in future growth prospects.
- Operational Efficiency Gains: The restructuring plan, expected to be completed by mid-2028, is projected to achieve approximately $50 million in annual pretax cost savings, further optimizing operational efficiency and strengthening competitive positioning in the market.
See More
Teleflex Q1 Financial Results: Revenue Up 32.3%
- Significant Revenue Growth: In Q1 2026, Teleflex reported revenue from continuing operations of $548.3 million, reflecting a 32.3% year-over-year increase, with a 5.1% rise on a pro forma adjusted constant currency basis, indicating strong performance in the medical technology sector.
- Earnings Per Share Fluctuation: The GAAP diluted EPS was $(0.11), a sharp decline from $1.14 in the prior year, while the adjusted diluted EPS stood at $1.39, slightly below last year's $1.44, reflecting challenges during the company's transformation phase.
- Stable Future Outlook: The company maintains its 2026 GAAP revenue growth guidance range of 14.40% to 15.40%, and expects adjusted diluted EPS to be between $6.25 and $6.55, demonstrating management's confidence in future performance.
- Strategic Restructuring Progress: Newly appointed CEO Jason Weidman will take office on June 8, 2026, and in conjunction with the upcoming strategic divestitures, Teleflex plans to utilize proceeds for a $1 billion share repurchase and $800 million debt repayment to enhance financial flexibility and support future growth.
See More
Teleflex Q1 Earnings Announcement Scheduled
- Earnings Release Date: Teleflex (TFX) is set to announce its Q1 earnings on May 7 before market open, with a consensus EPS estimate of $1.22, reflecting a significant year-over-year decline of 58.1%, indicating substantial profitability challenges for the company.
- Revenue Decline Forecast: The expected revenue for Q1 is $537.59 million, down 23.3% year-over-year, highlighting the overall weakness in the medical device sector and the challenges faced by Teleflex in the market.
- Historical Performance Review: Over the past two years, Teleflex has beaten EPS estimates 100% of the time and revenue estimates 63% of the time, although recent EPS estimates have seen no upward revisions, indicating analysts' cautious outlook on the company's future performance.
- Estimate Revision Trends: In the last three months, EPS estimates have experienced 7 downward revisions with no upward adjustments, while revenue estimates saw 1 upward revision and 6 downward revisions, suggesting a weakening market confidence in Teleflex's future earnings.
See More
